Full Text Journal Articles by
Author Kenneth M Verburg

Advertisement

Find full text journal articles






Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.

Mark T Brown, Paola Sandroni, Phillip A Low, Kenneth C Gorson, David J Hunter, Glenn C Pixton, Robert J Fountaine, Lars Viktrup, Christine R West, Kenneth M Verburg,

<h4>Objective</h4>To assess the long-term neurological safety of tanezumab, a monoclonal antibody against nerve growth factor.<h4>Methods</h4>Patients with osteoarthritis of the hip or knee received stable doses of oral nonsteroidal anti-inflammatory drugs (NSAIDs) before study entry and during a ≤ 37-day screening period. Patients were randomized 1:1:1 to double-dummy tanezumab (2.5 mg or 5 mg, subcutaneous ... Read more >>

J Neurol Sci (Journal of the neurological sciences)
[2022, 434:120184]

Cited: 0 times

View full text PDF listing >>



Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.

Tuhina Neogi, David J Hunter, Melvin Churchill, Ivan Shirinsky, Alexander White, Ali Guermazi, Masanari Omata, Robert J Fountaine, Glenn Pixton, Lars Viktrup, Mark T Brown, Christine R West, Kenneth M Verburg,

<h4>Background</h4>A recent phase 3 study demonstrated that treatment with tanezumab, a nerve growth factor inhibitor, or nonsteroidal anti-inflammatory drugs (NSAIDs) improves pain and physical function in participants with moderate-to-severe osteoarthritis (OA) of the hip or knee. Here, we evaluated the time course and clinical importance of these initial efficacy findings ... Read more >>

Arthritis Res Ther (Arthritis research & therapy)
[2022, 24(1):78]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

0.4637 s